Cancer Medicine

We conducted genetic analyses of IKZF1 deletion, point mutation of JAK2 exon 16, 17, and 21, CRLF2 expression, the presence of P2RY8-CRLF2 fusion and F232C mutation in CRLF2 in 202 pediatric BCP-ALL patients newly diagnosed and registered in Japan Childhood Leukemia Study ALL02 protocol to find out if IKZF1 deletion had reduced event-free survival and overall survival. JAK2 mutations and P2RY8-CRLF2 fusion were rarely detected. IKZF1 deletion was identified as adverse prognostic factor even in pediatric BCP-ALL showing good response to PSL.

In New Jersey, for many common cancers, uninsured and Medicaid insured patients have significantly higher risks of death than privately insured patients even after adjustment for other demographic and clinical factors. While ensuring that everyone has adequate health insurance is an important step, additional measures must be taken to address cancer survival disparities.

In this study, we first immunolocalized aromatase using immunohistochemistry in patients with liver cirrhosis, steatosis, hepatitis, hepatocellular carcinoma (HCC), and metastasis liver carcinoma (MLC) in order to study the detailed status of intrahepatic aromatase. Aromatase immunoreactivity was predominantly detected in non-neoplastic hepatocytes around tumor cells. These findings all indicated that carcinoma cells, whether metastatic or primary, induced aromatase expression in adjacent normal hepatocytes through the potential soluble aromatase inducible factors in human hepatic microenvironments.

We performed a retrospective analysis of non-small-cell lung cancer patients from a double-blind phase III trial of thalidomide versus placebo, in addition to standard chemotherapy. Among 150 patients with squamous cell cancer who had stable disease or complete/partial response after completing the second chemotherapy cycle, there was a 25% reduction in the death rate and 31% reduction in the risk of progressing or dying. We describe a potentially effective treatment strategy, in which a patient group is enriched using both histology and an early assessment of response during standard chemotherapy, and where a new agent is given for the remainder of chemotherapy and as maintenance.

This study of EGFR, KRAS, BRAF and HER-2 mutational status in 77 brain metastases from non-small cell lung cancer (NSCLC) reveals a low frequency of EGFR mutations whereas KRAS mutations are as frequent as in primitive NSCLC. These results raise the question of the variability of brain metastatic potential of NSCLC cells in relationship to mutation patterns.

The selection of a screening test is important to detect clinically relevant cases of Human papillomavirus (HPV) infection while avoiding the unnecessary cost, stress and compromise of the cervix to patients associated with over-treating mild cytological abnormalities. Given the clinical relevance and importance of cervical cancer worldwide, our results support the use of Hybrid Capture II (HCII) in cervical screening programs.

A comprehensive colonoscopy-screening program results in high-quality screening with high detection of adenomas, advanced adenomas, serrated adenomas, and multiple adenomas.

TAS-106 was reasonably tolerated in patients with platinum-failure HNSCC and NPC with the 24-h continuous infusion administration schedule; however, there was no anti-tumor efficacy seen with TAS-106 monotherapy. Future studies will focus on TAS-106 combinations and mechanisms of drug resistance.

This clinic-based study aimed to evaluate the impact of Breast cancer (BC) molecular subtypes in on survival in Puerto Rico. Consistent to results in other populations, the triple-negative subtype and HER-2+ tumors were associated with decreased survival.

In the contemporary setting, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) are associated with a low mortality and improved survival. When present, complications are associated with a decreased overall survival. This treatment modality should be considered within the context of multidisciplinary care for select peritoneal carcinomatosis patients.

This is a phase I study for determining the recommended dose of daily everolimus administered orally in combination with mitomycin C, administered every 3 weeks to patients with metastatic gastric cancer or adenocarcinoma of the esophagogastric junction.

In a transgenic mouse model of neuroblastoma with bilateral adrenal gland tumors, combination therapy with doxorubicin (DXR) and gefitinib strongly inhibited tumor growth than treatment with DXR or gefitinib alone, as assessed by magnetic resonance imaging.

Phosphatase and tensin homologue (PTEN) remains controversial as a predictive and prognostic marker. There also remains uncertainty as to the best method to assess PTEN status. Here, we use PTEN copy number and assess the association of outcome and PTEN loss, as defined by copy number variation.

Remarkable inhibitory effects of hybrid liposomes (HL-23) composed of l-α-dimyristoylphosphatidylcholine and polyoxyethylene(23) dodecyl ether on the metastatic growth of murine osteosarcoma (LM8) cells were obtained in vitro. HL-23 significantly inhibited the primary tumor growth of LM8 cells in the homograft mouse models along with apoptosis. Furthermore, HL-23 drastically inhibited the lung metastasis of LM8 cells in the mouse models through the inhibition of invasion.

This study was designed to evaluate the effects of dual inhibition of the vascular endothelial growth factor axis and the thrombospondin axis on refractory solid tumors. We found signs of clinical activity in patients with various tumor types, though whether this was related to one or both agents is not known. We also found that plasma levels of stromal-derived factor 1 (SDF-1) and placental growth factor (PlGF) were elevated on combination therapy, consistent with prior published reports. These data suggest that combination anti-angiogenesis therapies may be clinically useful.